Materials and Instrumentation
DNAse/RNAse-free water was purchased from Fisher Scientific, Inc. (Pittsburgh, PA) and used for all buffers and for the stock solutions of oligonucleotides. Fluorogenic substrates (F-sub) were synthesised and HPLC purified by TriLink BioTechnologies, Inc. (San Diego, CA). All other oligonucleotides were obtained from Integrated DNA Technologies, Inc. (Coralville, IA). The oligonucleotides were dissolved in water and stored at -20 o C until needed. Stock concentrations of oligonucleotides were calculated by measuring the absorption of the solutions at 260 nm by using a Perkin-Elmer Lambda 35 UV/Vis spectrometer (San Jose, CA). Extinction coefficients of oligonucleotides were calculated by using OligoAnalyzer 3.1 software (Integrated DNA Technologies, Inc.). Fluorescent spectra were recorded on a Perkin-Elmer LS-55 luminescence spectrometer equipped with a Hamamatsu xenon lamp. Experiments were performed at excitation wavelength of 485 nm. Emission of FAM was monitored at 517 nm. Excitation and emission slits were both 10 nm. For the detection of genuine sequences, fluorescence emission was measured using an Applied Biosystems StepOne real-time PCR.
Detailed Experimental Procedures
Fluorescence of sample mixtures were measured in comparison to two blanks, first blank is the 200 nM F-sub in the buffer (50 mM HEPES, pH 7.4, 50 mM MgCl 2 , 20 mM KCl, 120 mM NaCl, 0.03% Triton X-100%, and 1% DMSO) only and the second blank is the 200 nM F-sub and deoxyribozyme (DZa and DZb) of the three groups as 7 nM DZa-I, 15 nM DZb-I, 12 nM DZa-II, 30 nM DZb-II, 2 nM DZa-III, and 30 nM DZb-III in the same buffer. Fluorescence of 10 nM of each EV-71 synthetic analytes and 10 nM of each CV-A16 synthetic analytes were measured after 1 hour and 3 hours of incubation at 28 o C. Limit of detection were determined for EV-III-5 and of EV-I-1 analytes after 1 and 3 hours of incubation at 28 o C. In the measurement of genuine sequences, the synthetic sequence analytes were replaced with the Lambda exonuclease-treated PCR products. The PCR products (10 L) were incubated with 6 unit of Lambda Exonuclease (New England Biolabs) at 37 °C for 30 min, followed by enzyme inactivation at 75 °C for 10 min. After the reaction with lambda exonuclease, the ssPCR products (20 L) were mixed with sodium acetate (final concentration of 0.3 M) and 75 L ethanol, followed by vortex mix thoroughly. The mixture was stored at 20 °C overnight and subsequently was centrifuged at 14,000  g for 20 min at 4 °C. The supernatant was taken away; the pellet was slowly rinsed with 200 L of 95% ethanol. Then the sample was dried under vacuum and was re-suspended in 192.5 L buffer. The above solution was mixed with the six adaptor strands and F-sub for the fluorescence measurements in a total volume of 220 L. The control sample was prepared by performing same PCR in the absence of viral cDNA.
3. RNA extraction, RT-PCR, and PCR RNA extraction. Viral RNA was extracted from the clinical specimens (throat swab culture) using a NucleoSpin® RNA Virus (Macherey-Nagel, Germany). Briefly the cell culture supernatant (150 L) was incubated with RAV1 buffer (600 L) at 4 °C for 10 min, followed by a mixing with 100% ethanol (600 L). An aliquot (650 L) of the mixed solution was transferred to a NucleoSpin® RNA Virus Columns and was centrifuged at 8,000 rpm for 1 min and the filtrate was removed. Subsequently the procedure containing washing (using 600 L ethanol-added wash buffer) and centrifugation (13,000 rpm for 3 min) was iterated twice. The RNA was eventually eluted with pre-heated (70 °C) RNAse-free water (30 L) under 13,000 rpm for 2 min.
Reverse transcription-PCR (RT-PCR).
The IQ2 MMLV RT-script & cDNA synthesis accessory kit (Bio Genesis, Taiwan) was used for the reverse transcription-PCR. A primer (5'-CCYTGYTCCATNRCNTCNTC) was designed by using OligoAnalyzer 3.1 and used to produce cDNA given from the templates of EV-E59 and EV-B5/141 viral RNAs. The RNA (400-500 ng) was incubated with the primer (10 M) at 65 °C for 2 min, then the mixture was immediately put onto ice bath for 1 min. RT-PCR was performed by mixing the RNA/primer mixture (10 L), dNTP (1 L, 10 mM), DTT (2 L, 0.1 M), RNase inhibitor (20 U/L), and HiScript I Reverse Transcriptase (5 U/L) in 1X First-Strand Buffer with a total volume of 20 L, subsequently heated at 42 °C for 90 min and 85 °C for 5 min. The cDNA obtained was stored at 20 °C until a use.
Polymerase Chain Reaction (PCR).
The forward (5'-GGGCCATCTACGTGGG) and reverse (5'-/Phos/GGTAATACTCGCTAGCTTCCAC, Phos refers to a phosphorylation terminal end) for amplification of EV-E59 and EV-B5/141 were designed by the OligoAnalyzer 3.1. The PCR product was generated from a 10 μL PCR mixture composed of dNTP (200 μM), FP (0.5 μM), RP (0.5 μM), cDNA (1 μL), and Phusion Hot Start II High-Fidelity DNA Polymerase (0.02 U/L) in 1X Phusion GC buffer. Reactions were performed with 60 cycles of PCR in MiniOpticon TM Thermal Cycler (BioRad). The amplification cycles included 1 cycle of 2 min at 98 °C, followed by 60 cycles containing 98 °C for 10 s, 61.5 °C for 30 s, and 72 °C for 30 s, and the last extension at 72 °C for 10 min, before returning to 4 °C for 10 min.
Sequence selection
Genome of enterovirus consists of approximately 7500 nucleotides that include an open reading frame (ORF) and untranslated regions (URTs) franked by 5' and 3' terminal. The ORF was divided into three domains, P1, P2, and P3, which encodes polyproteins containing VP1-4, 2A-2C and 3A-3D, respectively [1] . To select the targeted fragments specific to EV71, all the enterovirus sequences deposited in GenBank were downloaded. Genotype classification of these enterovirus sequences were examined by comparing them with the classification results obtained from EVIDENCE [2] . Incongruent genotype assignments between GenBank and EVIDENCE were excluded. The obtained sequences were further separated into EV71 and non-EV71 sequences to produce 8455 EV71 sequences. Subsequently the nucleotide regions corresponding to the 11 polyproteins in each sequence were defined. It was found that 15-base was the longest nucleotide length which was conserved in EV71 sequences. As a result, more than 387,000 oligonucleotide fragments (each is 15-nt) were obtained from the 8455 EV71 sequences. However, the enterovirus sequences are highly mutated; neither the 15-nt fragment was able to represent all EV71 isolates. We therefore performed three-fragment combination (3-combination) to represent EV71, that is basically the OR gate concept of the study. Since there produced great number of the combinations, we further reduced the data size by excluding the fragments which either represent less than 30% of whole EV71 isolates or are present in non-EV71 sequences, which produced the no. of fragments and 3-combinations revealed in Table S1 . Coverage rate of the 3-fragment combination in each protein region was also estimated. Notably, although the highest coverage rate (93.3%) was obtained for VP4, one of its targeted fragments, GTTTGCAAATCCTGT, was present in the lately submitted CV-A16 isolate (KU163608.1). Similarly, the fragments selected for VP2 and VP3 also appeared in CV-A16 and CVA10 isolates, respectively. To ensure a high selectivity of the sensors, we selected the fragments obtained from 2A (CTTTAGAGTGGTCAA, TTGGGAAGACAGCTC, and ACCCAGCCTCATATA) to be the EV71-specific fragments which achieved a 90.5%-coverage rate. It should be furthermore noted that the 15-nt targeted fragments were insufficiently long to bind with the two adaptor strands (DZa and DZb) stably, which hampered the formation of BiDZ catalytic core. We therefore made 3-nt extensions at both 5' and 3' terminals of the selected targeted fragments to produce 21-nt targets. Because the 1st and the 19th nucleotide (counted by 5'  3') of the 21-nt targets were generally variable, different targets containing two nucleotide substitutions were designed in accordance with the varied nucleotides present in the isolates. The corresponding GenBank accession numbers are depicted in Table S2 . In addition, degenerate probes of DZa and DZb were also designed for high hybridization efficiency.
For the selectivity study, eight Coxsackievirus sequences containing one to three nucleotide variations from EV71 isolates were selected. The corresponding GenBank accession numbers are indicated in Table S2 . The samples were analyzed by 20% PAGE containing 7 M urea followed by staining with SYBR Gold (Thermofisher) and imaging using BioRad GelDoc XR+ system. The mobility of stands in the gel are indicated by arrows on the side of the picture. The fluorescent product of F-sub cleavage is indicated by the red arrows. B) The samples were composed as described for panel A followed by fluorescent measurement using QuantStudio™ 6 at a constant temperature of 28 o C every 1 min over 6 hrs.
We further analyzed the reaction mixtures containing OR gates using denaturing polyacrylamide gel electrophoresis (Fig. S3 A) . The product of F-sub cleavage was observed only in the presence of complementary EV-1-2 and mismatched Cox-II-1 analytes (indicated by red arrows in Fig. S3A ), which is consistent with the fluorescent results reported in the main text (Fig.2) . No substrate cleavage was observed in the absence of analytes (Lane 2) or in the presence of mismatched (Cox-I-1, Cox-I-2, Cox-II-2 and Cox-II-3, lanes 4, 5, 7 and 8, respectively).
Measurement of kinetics of fluorescent response revealed significant fluorescent increase over time only in the presence of fully complementary EV-1-2 and mismatched Cox-II-1 analytes in accordance with data of Fig 2 and Fig. S3, panel A. 
